Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.69 USD
Change Today +0.02 / 0.75%
Volume 10.3K
As of 9:43 AM 06/3/15 All times are local (Market data is delayed by at least 15 minutes).

cellceutix corp (CTIX) Snapshot

Open
$2.69
Previous Close
$2.67
Day High
$2.69
Day Low
$2.62
52 Week High
12/12/14 - $4.93
52 Week Low
08/1/14 - $1.60
Market Cap
316.7M
Average Volume 10 Days
289.7K
EPS TTM
$-0.11
Shares Outstanding
117.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELLCEUTIX CORP (CTIX)

Related News

No related news articles were found.

cellceutix corp (CTIX) Related Businessweek News

No Related Businessweek News Found

cellceutix corp (CTIX) Details

Cellceutix Corporation, a clinical stage biopharmaceutical company, focuses on discovering and developing small molecule drugs to treat drug-resistant cancers, psoriasis, autism, and inflammatory diseases. Its flagship compounds include Kevetrin, an anti-cancer compound that is in Phase I clinical trial for the treatment of cancer; Prurisol, an anti-psoriasis drug candidate that has completed Phase I clinical trial; and Brilacidin, an antibiotic candidate for the treatment of diabetic foot ulcer infections, and other indications, such as ophthalmic and otitic infections, as well as for other skin infections and oral mucositis. The company’s preclinical stage compounds comprise KM 391 for the treatment of autism; KM 277 for the treatment of rheumatoid arthritis; KM 278 for the treatment of arthritis/asthma; KM 362 for the treatment of MS/ALS/Parkinson’s disease; KM-3174 for the treatment of cancer; and KM-732 for hypertensive emergency, as well as Delparantag, a synthetic small-molecule for the treatment of other diseases, including chronic obstructive pulmonary disease. In addition, its other product candidates include compounds active against other gram-negative bacterias, malaria, tuberculosis, biowarfare pathogens, and PolyCide antimicrobial biomaterials. The company was founded in 2007 and is headquartered in Beverly, Massachusetts.

9 Employees
Last Reported Date: 09/15/14
Founded in 2007

cellceutix corp (CTIX) Top Compensated Officers

Chairman, Chief Executive & Financial Officer...
Total Annual Compensation: $444.7K
President, Chief Scientific Officer and Direc...
Total Annual Compensation: $444.7K
Compensation as of Fiscal Year 2014.

cellceutix corp (CTIX) Key Developments

Cellceutix Corporation Opens Enrollment in Phase 2 Clinical Trial of Brilacidin-OM

Cellceutix Corporation announced that a second site opened enrollment in the company's Phase 2 clinical trial of Brilacidin-OM for the prevention and treatment of oral mucositis in head and neck cancer patients undergoing chemoradiation. Clinical sites in Oregon and South Dakota are now enrolling patients to evaluate Brilacidin-OM for efficacy with additional sites to be added in June to keep the trial progressing in a timely manner. Besides targeting the huge unmet medical need for an effective therapeutic for oral mucositis, the Brilacidin-OM trial has significant implications for Cellceutix shareholders. Should the anti-inflammatory properties of Brilacidin-OM work in the trial as anticipated, Cellceutix will immediately turn its attention to inflammatory diseases, such as hidradenitis suppurativa (HS) and gastrointestinal diseases, as planned. Cellceutix believes the potential market size for its defensin mimetics as anti-inflammatory compounds is even greater than the substantial market for antibiotic applications.

Cellceutix Corporation Announces Earnings Results for the Third Quarter Ended March 31, 2015

Cellceutix Corporation announced earnings results for the third quarter ended March 31, 2015. For the quarter, the company reported net loss was $2.9 million, or 2 cents per share, compared to a net loss of $2.33 million, or 2 cents per share, for the quarter ended March 31, 2014.

Cellceutix Corporation Announces Board Changers

Cellceutix Corporation announced the selection of Dr. Barry Alan Schechter, Dr. Zorik Spektor and Mark Tobin as qualified independent directors of the company's Board of Directors. Dr. Schechter, is the Director of Department of Cornea and External Disease at Florida Eye Microsurgical Institute from the year 2005 to the present. Dr. Spektor is Director of The Center for Pediatric ENT - Head and Neck Surgery in Boynton Beach, Florida from the year 1995 to the present. In addition, he is a Voluntary Assistant Professor of Surgery at the Department of Otolaryngology, University of Miami Leonard M. Miller School of Medicine. He is also an Affiliate Clinical Assistant Professor of Biomedical Science at Florida Atlantic University in Boca Raton, Florida. Mark Tobin is Director of Research at Digital Offering, a merchant bank, from October 2013 to the present. In addition, he is a Managing Partner at Tobin Tao & Company from February 2013 to the present. Previously, from May 2005 to February 2013, Mr. Tobin served as Director of Research and as a Senior Research Analyst at Roth Capital Partners.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CTIX:US $2.69 USD +0.02

CTIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CTIX.
View Industry Companies
 

Industry Analysis

CTIX

Industry Average

Valuation CTIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 34.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLCEUTIX CORP, please visit www.cellceutix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.